Evercore ISI Group Initiates Coverage On Mineralys Therapeutics with Outperform Rating
Evercore ISI Group analyst Umer Raffat initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Outperform rating.
Credit Suisse Initiates Coverage On Mineralys Therapeutics with Outperform Rating, Announces Price Target of $40
Credit Suisse analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Outperform rating and announces Price Target of $40.
Guggenheim Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $32
Guggenheim analyst Seamus Fernandez initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $32.
B of A Securities Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $39
B of A Securities analyst Greg Harrison initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $39.
Stifel Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $45
Stifel analyst Annabel Samimy initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $45.
Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Reported Late Thursday Feb 9, Mineralys Therapeutics Announces Pricing Of $192M Upsized Initial Public Offering Of 12M Shares Of Common Stock At A Price Of $16/Share
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the pricing of its